About Aimmune Therapeutics
Aimmune Therapeutics is a company based in San Mateo (United States) founded in 2011 was acquired by Nestlé Health Science in August 2020.. Aimmune Therapeutics has raised $177 million across 6 funding rounds from investors including Fidelity Investments, RA Capital and Nestlé Health Science. The company has 250 employees as of December 31, 2022. Aimmune Therapeutics operates in a competitive market with competitors including BeiGene, Vir Biotechnology, Cidara Therapeutics, BioNTech and Decibel Therapeutics, among others.
- Headquarter San Mateo, United States
- Employees 250 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
$-248.5 M-18as on Dec 31, 2019
-
EBITDA
$-249.8 M-16as on Dec 31, 2019
-
Total Equity Funding
$177 M (USD)
in 6 rounds
-
Latest Funding Round
$200 M (USD), Post-IPO
Feb 05, 2020
-
Investors
Fidelity Investments
& 8 more
-
Employee Count
250
as on Dec 31, 2022
-
Acquired by
Nestlé Health Science
(Aug 30, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Software Development Team
218 people
Sales and Marketing
142 people
Leadership Team
111 people
Human Resources and Administration
70 people
Senior Team
65 people
Product Management Team
61 people
Finance and Accounting
49 people
Head Team
45 people
Unlock access to complete
Funding Insights of Aimmune Therapeutics
Aimmune Therapeutics has successfully raised a total of $177M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $200.0M
-
First Round
First Round
(21 Nov 2013)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2020 | Amount | Post-IPO - Aimmune Therapeutics | Valuation |
investors |
|
| Nov, 2018 | Amount | Post-IPO - Aimmune Therapeutics | Valuation |
investors |
|
| Nov, 2016 | Amount | Post-IPO - Aimmune Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aimmune Therapeutics
Aimmune Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, RA Capital and Nestlé Health Science. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on life science sector
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aimmune Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aimmune Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aimmune Therapeutics Comparisons
Competitors of Aimmune Therapeutics
Aimmune Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Vir Biotechnology, Cidara Therapeutics, BioNTech and Decibel Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Medicines are developed to protect, repair, and restore hearing capacity.
|
|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aimmune Therapeutics
Frequently Asked Questions about Aimmune Therapeutics
When was Aimmune Therapeutics founded?
Aimmune Therapeutics was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Where is Aimmune Therapeutics located?
Aimmune Therapeutics is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Who is the current CEO of Aimmune Therapeutics?
Andrew Oxtoby is the current CEO of Aimmune Therapeutics.
Is Aimmune Therapeutics a funded company?
Aimmune Therapeutics is a funded company, having raised a total of $177M across 6 funding rounds to date. The company's 1st funding round was a Post-IPO of $156.7M, raised on Nov 21, 2013.
How many employees does Aimmune Therapeutics have?
As of Dec 31, 2022, the latest employee count at Aimmune Therapeutics is 250.
What does Aimmune Therapeutics do?
Aimmune Therapeutics is a clinical-stage biopharmaceutical company working in the development of product candidates, for the treatment of peanut and other food allergies. They recently completed a Phase 2 study of its lead product, AR101, a highly characterized, complex mixture of naturally occurring proteins and pharmaceutical-grade inactive ingredients for the treatment of peanut allergy. They claim to initiate a second development program, for egg allergy.
Who are the top competitors of Aimmune Therapeutics?
Aimmune Therapeutics's top competitors include BeiGene, BioNTech and Decibel Therapeutics.
Who are Aimmune Therapeutics's investors?
Aimmune Therapeutics has 9 investors. Key investors include Fidelity Investments, RA Capital, Nestlé Health Science, Food Allergy Research & Education, and Longitude Capital.